Immunic（IMUX）上載投資者簡報，聚焦vidofludimus calcium進展性MS第三期臨床計劃

false
 0001280776
 
 
 
 
 
 
 
 0001280776
 
 
 2026-07-14
 2026-07-14
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):
July 14, 2026

 

IMMUNIC, INC.

(Exact name of registrant as specified in its
charter)

 

 
 Delaware
 001-36201
 56-2358443

 
 (State or other jurisdiction

of incorporation)
 (Commission File Number)
 (IRS Employer Identification No.)

 
 

1200 Avenue of the Americas, Suite 200

New York, NY 10036

USA

(Address of principal executive offices)

 

Registrant’s telephone number, including
area code: (332) 255-9818 

 

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 
 ☐
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
  
  

 
 ☐
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
  
  

 
 ☐
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 
  
  

 
 ☐
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

Securities registered pursuant to Section 12(b) of the Act:

 

 
 Title of each class
 Trading Symbol(s)
 Name of exchange on which registered

 
 Common Stock, par value $0.0001
 IMUX
 The Nasdaq Stock Market LLC

 
 

Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. Yes ☐ No ☐

 

  

  

 

 

Item 7.01. Regulation FD Disclosure

 

On July 14, 2026, Immunic, Inc. a Delaware
corporation (the “Company” or “Immunic”)
made available an updated presentation (the “Presentation”) on the Company's website.

 

The Presentation is attached as Exhibit 99.1 to
this Current Report on Form 8-K, and is incorporated herein by reference.

 

The information in Item 7.01 of this Current Report
on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for the purposes of Section 18 of the Securities
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it
be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth therein.

 

Cautionary Note Regarding Forward-Looking
Statements

 

Certain statements in this Current Report on Form
8-K and the Presentation are “forward-looking statements” that involve substantial risks and uncertainties for purposes of
the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical
facts, included in this Current Report on Form 8-K, and the Presentation regarding strategy, future operations, future financial position,
future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials,
prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited
to, statements relating to Immunic's development programs and the targeted diseases; the potential for vidofludimus calcium to safely
and effectively target diseases; preclinical and clinical data for vidofludimus calcium; the feasibility of advancing vidofludimus calcium
to a confirmatory phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials, anticipated
clinical milestones and regulatory approvals; the nature, strategy and focus of the company and further updates with respect thereto;
the development and commercial potential of any product candidates of the company; Immunic’s continued listing on The Nasdaq Capital
Market; and expectations regarding the capitalization, resources and ownership structure of the company and its executive and board structure.
Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking
statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s
current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those
projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs
and macroeconomics trends, impacts of the Ukraine - Russia conflict and the conflict in the Middle East on planned and ongoing clinical
trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future
liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational
requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial
results, any changes to the size of the target markets for the company’s products or product candidates, the protection and market
exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process
and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other
factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal
year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company’s subsequent filings with the SEC. Copies
of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this Current Report
on Form 8-K and the Presentation speaks only as of the date of this Current Report on Form 8-K, and the Presentation. Immunic disclaims
any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which
they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents
of this Current Report on Form 8-K and the Presentation.

 

Item 9.01. Financial Statements and Exhibits.

 

 
 Exhibit
 Description

 
 99.1
 Presentation, dated July 14, 2026

 
 104
 Cover Page Interactive Data File (formatted as Inline XBRL).

 
 

  

  

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

 
 Dated: July 14, 2026
 Immunic, Inc.

 
  
  
  

 
  
 By:
 /s/ Erik Lundgren

 
  
  
 Erik Lundgren 

 
  
  
 Chief Executive Officer